Rapport Therapeutics financials
$33.02−1.26%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $20.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $20.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | 100.0% | — | — | — | — | — | — | — |
| Operating income | -$60.8M | -$24.2M | -$38.5M | -$30.0M | -$29.5M | -$27.1M | -$23.5M | -$21.6M | -$20.8M |
| Net income | -$56.6M | -$19.9M | -$33.8M | -$26.9M | -$26.7M | -$24.1M | -$20.0M | -$17.5M | -$18.1M |
| Net margin | — | −99.3% | — | — | — | — | — | — | — |
| Diluted EPS | $-1.19 | $-0.42 | $-0.72 | $-0.71 | $-0.75 | $-0.68 | $-0.56 | $-0.50 | $-1.70 |
| EBITDA | -$60.6M | -$24.0M | -$38.2M | -$29.7M | -$29.2M | -$26.9M | -$23.3M | -$21.4M | -$20.6M |
| Operating cash flow | -$41.5M | -$13.1M | -$24.7M | -$17.5M | -$25.1M | -$20.2M | -$14.4M | -$16.4M | -$16.4M |
| Free cash flow | -$41.5M | -$13.1M | -$24.9M | -$17.6M | -$25.1M | -$20.5M | -$14.7M | -$16.6M | -$17.3M |
| Diluted shares | 47.5M | 47.2M | 47.1M | 37.9M | 35.4M | 35.3M | 35.4M | 34.9M | 10.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $63.6M | $78.1M | $52.6M | $251.4M | $55.1M | $57.6M |
| Short-term investments | $372.5M | $398.7M | $437.9M | $261.7M | $205.4M | $227.8M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $459.0M | $497.6M | $512.4M | $535.3M | $285.5M | $302.1M |
| Total liabilities | $36.1M | $26.1M | $27.8M | $23.7M | $22.0M | $16.2M |
| Shareholders' equity | $422.9M | $471.5M | $484.7M | $511.6M | $263.5M | $285.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology